



HHS Public Access

Author manuscript

Neurochem Res. Author manuscript; available in PMC 2016 December 01.

Published in final edited form as:

Neurochem Res. 2015 December ; 40(12): 2527–2543. doi:10.1007/s11064-015-1600-7.

Metabolic alterations in developing brain after injury – knowns and unknowns

Mary C. McKenna¹, Susanna Scafidi², and Courtney L. Robertson²

¹Department of Pediatrics and Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA 21201

²Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

Brain development is a highly orchestrated complex process. The developing brain utilizes many substrates including glucose, ketone bodies, lactate, fatty acids and amino acids for energy, cell division and the biosynthesis of nucleotides, proteins and lipids. Metabolism is crucial to provide energy for all cellular processes required for brain development and function including ATP formation, synaptogenesis, synthesis, release and uptake of neurotransmitters, maintaining ionic gradients and redox status, and myelination. The rapidly growing population of infants and children with neurodevelopmental and cognitive impairments and life-long disability resulting from developmental brain injury is a significant public health concern. Brain injury in infants and children can have devastating effects because the injury is superimposed on the high metabolic demands of the developing brain. Acute injury in the pediatric brain can derail, halt or lead to dysregulation of the complex and highly regulated normal developmental processes. This paper provides a brief review of metabolism in developing brain and alterations found clinically and in animal models of developmental brain injury. The metabolic changes observed in three major categories of injury that can result in life-long cognitive and neurological disabilities, including neonatal hypoxia-ischemia, pediatric traumatic brain injury, and brain injury secondary to prematurity are reviewed.

Introduction

The mammalian brain is dependent on a constant supply of oxygen and nutrients, both from dietary intake and provided by other organs, which are delivered to the brain via circulation [1, 2]. The developing brain controls the function of body organs through neurotransmission, while simultaneously facing the metabolic demands of its' own growth and maturation. Brain development is an energy expensive process; hence, during infancy and childhood there is a continuous increase in cerebral blood flow and glucose utilization [3, 4].

Glucose and substrates present in mammalian milk including ketones, fatty acids and glycerol are used to meet the high metabolic demands of the developing brain, whereas adult

Address correspondence and reprint requests to: Mary C. McKenna, Ph.D., Department of Pediatrics, University of Maryland School of Medicine, 655 W. Baltimore St., Room 13-019, Baltimore, MD, 21201 United States, mmckenna@umaryland.edu.

brain uses glucose as the primary energy substrate [2–4]. Recognition that the immature brain uses a variety of substrates for energy and biosynthetic processes led to extensive research to characterize temporal and regional changes in brain development and metabolism [3–5].

Early studies demonstrated high circulating levels and uptake of ketones and lactate [2, 5, 6] as well as glucose, whereas positron emission tomography (PET) studies revealed regional differences in uptake and use of glucose that correlated with developmental maturation of brain function [3, 4, 7].

Uptake and utilization of substrates depends on the presence of specific glucose and monocarboxylic acid transporters (MCT) and the activity of enzymes required for metabolism (see Table 1). Glucose and the MCT transporters responsible for lactate and ketone body uptake show regional and temporal changes in both human [8] and rodent brain [9] which parallel the developmental transition from lower glucose use in suckling brain to the high glucose use by adult brain (Table 1). The enzymes for substrate use undergo a coordinated maturation; with those for ketone body utilization peaking during early development then decreasing after the suckling period in rodents, while enzymes for glucose metabolism and TCA cycle activity increase several-fold from birth and mature between 20–40 days of age in rodents [1, 10–12]. Rates of TCA cycle flux and neurotransmitter cycling increase at least 3-fold from postnatal day 10 to 30 [13]. (Table 1).

The developing brain utilizes many substrates including glucose, ketone bodies, lactate, fatty acids and amino acids for energy and biosynthesis of lipids and proteins [1, 5, 6, 10, 13]. Metabolism is crucial to provide energy for all cellular processes including ATP formation, cell division, synaptogenesis, synthesis, release and uptake of neurotransmitters, maintaining ionic gradients, and maintaining reduced glutathione and redox status [1]. Metabolism is also crucial for synthesis of proteins, nucleic acids, carbohydrates and membrane lipids needed for mitochondrial function and myelination [1]. Although oxidation of glucose via the TCA cycle for energy is lower in developing brain, metabolism of glucose via the pentose phosphate pathway is higher than in adults and provides necessary precursors for nucleotide synthesis and the NADPH required for lipid biosynthesis and maintaining reduced glutathione [1, 10, 14, 15]. The ability to utilize ketones, lactate, pyruvate, free fatty acids and glycerol and certain amino acids also enables the developing brain to survive episodes of hypoglycemia [5, 6].

Developmental Brain Injuries that Can Lead to Poor Neurodevelopmental Outcome

A significant public health concern is the rapidly growing population of infants and children with neurodevelopmental and cognitive impairments [16–18]. Due to advancements in both neonatal and intensive care, more premature infants and children with neonatal or childhood brain injury survive with life-long disability [16,17]. A common misconception is that children with brain injury fare better than adults [19]. However, the pathology differs from adults, because in infants and children injury is superimposed on the highly orchestrated processes and high metabolic demands of the developing brain [19–25]. Acute injury in the

pediatric brain can derail or even halt normal developmental processes due to energy failure, disrupted cell division and synaptogenesis, impaired ionic gradients and depleted antioxidant capacity which can further impair metabolism [26–30].

The overall goal of this paper is to provide a brief review of metabolism in developing brain and the alterations found clinically and in animal models of developmental brain injury. We focus on three major categories of injury that can result in life-long cognitive and neurological disabilities, including brain injury secondary to prematurity, neonatal hypoxia-ischemia, and pediatric traumatic brain injury.

Brain Injury Related to Prematurity

Worldwide approximately 15 million infants are born prematurely, with ~1.5 million annual deaths attributable to preterm birth, especially in those very premature infants (<28 weeks gestation) [31]. Survival rates for premature neonates have increased over the last decades, with improvements in neonatal intensive care. However, the long-term morbidity from premature birth, especially as related to brain injury and abnormalities in brain development, has not significantly decreased. The neurologic deficits in premature infants are diverse, and include cerebral palsy, intellectual disability, sensory deficits, learning disabilities, attention deficits and problems with executive function [32, 33]. Many of these deficits persist throughout childhood and adolescence, requiring assistance in school and support for daily living activities. A longitudinal study showed that 72% of adolescents born very prematurely (<750 g birth weight) had school performance difficulties even without sensory or IQ impairments [33]. It is estimated that in the United States, ~5,000 annual cases of cerebral palsy, and ~10–20,000 cases of serious learning disabilities result from premature birth [32]. One of the most common conditions leading to neurologic injury in premature infants is periventricular leukomalacia (PVL), with diffuse white matter damage resulting from ischemia or inflammation in the vulnerable, immature white matter [32]. This process is believed to account for the majority of motor, cognitive and behavioral sequelae of prematurity; however, the biological basis for brain injury secondary to prematurity is complex and multifactorial. Animal models demonstrate the negative effects of prematurity on growth and maturation of multiple cell types throughout the brain, including neurons, astrocytes, and oligodendrocytes [29].

Neonatal Hypoxia-Ischemia

Neonatal hypoxia-ischemia (HI), which occurs in 1.8–6 per 1,000 live births, is a significant public health problem [26, 34–36]. A large proportion (~25%) of infants with perinatal hypoxia-ischemia develop life-long disabilities [37], which include intellectual disability, impaired learning, memory and executive function, seizure disorders and varying degrees of motor impairment [38, 39]. HI results in significant mortality and accounted for ~9% of all infant deaths in the US in 2005 [40]. Hypoxic-ischemic encephalopathy (HIE) is due to decreased delivery of oxygen and nutrients to brain, lactic acidosis and decreased clearance of CO₂ [26]. MRI and MRS studies reveal significant injury to deep gray matter including thalamus, hippocampus, putamen and basal ganglia; cortical loss is also observed but there is a relative sparing of cortex compared to other regions [26, 41–43]. While the causes of the

initial hypoxia-ischemia are multifactorial, the insult triggers a delayed cascade of molecular events resulting in progressing brain injury over time [26]. This insult leads to rapid energy failure, followed by a transient period of normalization of function for several hours, and a later secondary energy failure that ultimately can result in cell death [23, 24]. Hypothermia, the current therapeutic modality to prevent or attenuate secondary energy failure must be initiated within the first 6 hours of life and continued for 72 hr [24, 43]. Many randomized clinical trials demonstrated that therapeutic hypothermia decreases mortality without increasing disability in surviving children [16, 44]. While many prospective and retrospective studies show that therapeutic hypothermia is safe, assessing the long term outcomes of this intervention (up to adulthood) is still ongoing. A recent report by Massaro et al., [45] shows that this intervention is now offered to children with mild form of HIE. .

Pediatric Traumatic Brain Injury

Trauma is the leading cause of death in children ages 1–18, and traumatic brain injury (TBI) is the major determinant of functional outcome in injured children (NIH 1998). In the United States each year, approximately ½ million children sustain TBI with ~35,000 hospitalizations, and ~3,000 pediatric deaths from brain trauma [46]. Over the last 10 years, the rates of TBI-related Emergency Department visits have increased across all age groups, with children 0–4 years of age having the highest rate of any age group, and adolescents 15–19 years of age having the second highest rate [46]. Overall, the vast majority of TBI occurs in children and young adults [46].

The pathobiology of the response to biomechanical injury in a developing brain is distinct from that in adult TBI, and may require age-specific treatments [47]. In addition, while post-injury recovery in the adult is defined by return to pre-morbid functional level, the developing brain is dynamic. Developing children are expected to be continuously learning new skills, making the burden of TBI even greater. As a result, survivors of pediatric TBI suffer from many long-term physical, cognitive, psychological and social impairments [17, 18], and many of these deficits can persist into adulthood [48–50].

Alterations in Brain Metabolism After Developmental Brain Injury

Acute injury including neonatal hypoxia-ischemia and traumatic brain injury leads to rapid energy failure which is followed by a transient normalization of function and then a later secondary energy failure that ultimately leads to brain injury and poor neurodevelopmental outcome [23, 24]. Acute alterations in energy metabolism and prolonged metabolic dysregulation after neonatal and pediatric brain injury leave the brain vulnerable and unable to support many processes essential for normal development [20–24, 51]. Any injury superimposed on the high metabolic requirements of the rapidly developing brain can compromise normal developmental processes and lead to neurodevelopmental outcomes ranging from mild to severe learning disabilities [20–24]. Very premature infants often have neurodevelopmental disabilities; however, metabolic alterations in brain of premature infants are not well characterized.

Importance of Proton Magnetic Resonance Spectroscopy in Assessing Brain Injury

Magnetic Resonance Imaging (MRI) and proton Magnetic Resonance Spectroscopy (^1H -MRS) have become essential tools for studying brain injury in infants, children and adults [17–19, 47, 48]. ^1H -MRS is a non-invasive method for measuring metabolites that provide information about the structural and metabolic integrity of brain tissue. Importantly, ^1H -MRS can detect localized metabolic abnormalities, even in tissue that appears anatomically normal on other forms of MR imaging [52, 53]. Some studies have determined the absolute concentration of metabolites. Numerous studies over the past two decades have demonstrated that ratios of metabolites provide diagnostically relevant information about the severity of injury and are predictive of neurological outcome [20–22, 51, 52, 54].

N-acetylaspartate (NAA) is an amino acid synthesized in neuronal mitochondria which increases throughout early brain development, reaching a plateau at ~ 2 to 3 years of age [55, 56]. Reductions in NAA reflect severe alterations in neuronal mitochondrial function [56] and may reflect loss of viable neurons [55, 56]. NAA is released by neurons and taken up by oligodendroglial cells which use the acetyl moiety as a substrate for the synthesis of myelin lipids [1]. NAA can be detected in areas of active myelination during development [57, 58]. The presence of lactate in brain reflects anaerobic metabolism including impaired TCA cycle activity [56–58]. Presence of lactate is one of the earliest markers of brain injury in infants [56] and persistently elevated lactate is predictive of poor outcome [23]. The creatine-phosphocreatine pathway is essential for buffering ATP levels in brain [1]. Although Cr levels are considered to be relatively constant, decreased total and/or phosphocreatine levels reflect impaired energy status. Choline levels (tCho or Cho) increase in developing brain and the peak observed include free choline and choline containing phospholipids which are essential components of cell membranes and myelin [59]. Decreased choline can reflect cell loss; whereas increased choline can be a marker of increased membrane turnover, cellular proliferation and/or gliosis after injury [56, 59]. Myo-inositol is a key glial osmolyte that can increase in brain in response to edema [59]. Inositol containing phospholipids have important roles in signaling pathways involved in differentiation and cell growth in brain [60, 61].

The interpretation of ^1H spectroscopy in pediatric brain injury is challenging, as metabolite levels can change throughout normal brain development [62], with rapid maturational changes in the first year of life and slower changes through adolescence [63–65]. Ultimately, post-traumatic changes in ^1H -MRS in infants and children must be interpreted by comparison to age-matched reference data [55]. Although alterations in metabolite ratios provide useful clinical information, they do not give an in depth understanding of the mechanisms underlying energy failure subsequent to HI.

¹³C-Nuclear Magnetic Resonance Spectroscopy is Used to Determine Brain Metabolism

¹³C-Nuclear Magnetic Resonance (¹³C-NMR) spectroscopy is the most powerful technique for determining energy metabolism and neurotransmitter synthesis in brain [1, 66]. Specifically labeled forms of ¹³C-glucose are used to determine metabolism via glycolysis, the pentose phosphate pathway, synthesis of neurotransmitters glutamate and GABA and metabolism via the pyruvate carboxylase pathway and synthesis of glutamine in astrocytes [66]. Alterations in neuron → astrocyte and astrocyte → neuron trafficking of metabolites can also be determined by ¹³C-NMR since individual carbons of glutamate, glutamine and GABA are labeled from neuronal specific and glial specific pathways [66]. Since ¹³C-acetate is selectively taken up into astrocytes this precursor is used to determine metabolism via the astrocyte TCA cycle and trafficking from astrocytes → neurons [66]. Studies using ex vivo ¹³C-NMR have provided important information about alterations in specific pathways of metabolism in preclinical studies of brain injury [10, 66–69]. There are fewer in vivo studies and due to technical considerations including relatively low sensitivity, and due to the limitations using high field magnets there are a limited number of human studies. However, the greatly increased sensitivity of newer hyperpolarized ¹³C-NMR techniques holds great promise for determining metabolism in human brain. ¹³C-NMR can provide a functional readout of alterations in metabolism via neuronal and glial pathways in brain after injury and determine the efficacy of neuroprotective therapies.

Metabolic Alterations Associated with Prematurity

Clinical studies using magnetic resonance imaging (MRI) demonstrate significantly reduced gray matter volume (both cortex and subcortical structures), diffuse white matter injury, and abnormal development of temporal lobes and cerebellum in very premature infants [42, 70]. ¹H-MRS revealed decreased NAA levels in brain of very premature infants at term equivalent age and later time points [51, 71], consistent with changes observed in a recent animal study [72]. Preterm infants had lower GABA and glutamate in right frontal lobe than term controls and altered neonatal resting-state connectivity, (a measure of neural activity determined by assessing fluctuations in blood oxygen level dependent signal) [73, 74]. MRS showed increased lactate in areas of diffuse white matter injury in preterm infants and increased glutamine in punctate white matter lesions [75]. Bapat et al. [76] recently reported that decreased ratios of NAA/Cho in hippocampus, cortex and subventricular zone and decreased NAA/Myo-inositol ratio in subventricular zone in very low birth weight infants were associated with cognitive and language delay assessed at 18–22 months. Bluml et al. [30] reported altered metabolic maturation of white matter and disturbed synchronization of white matter and grey matter maturation that could contribute to neurological problems in preterm infants. These recent studies provide strong evidence of alterations in metabolism and connectivity, and asynchronous development in premature brain [30, 51, 71, 73, 76]. To date the metabolic alterations in brain of premature infants are not understood and remain poorly characterized. There is a paucity of preclinical data regarding specific alterations in transporter levels, substrate use, oxidative energy metabolism and antioxidant capacity (Table 2).

Metabolic Alterations in Neonatal Hypoxia-Ischemia

Magnetic Resonance Imaging (MRI) and proton Magnetic Resonance Spectroscopy (^1H -MRS) have become essential tools for studying brain injury in infants with hypoxia-ischemia [17–19, 72]. Such studies have provided important insights regarding brain changes after HI, and studies that also included neurological assessment at 12 months have demonstrated the power of ^1H -MRS data in predicting outcome [20–22]. A number of studies have reported that ratios of metabolites provide diagnostically relevant information and are predictive of neurological outcome [20–22]. A meta-analysis of prognostic accuracy of MR biomarkers and correlation with neurodevelopmental outcome at 1 year (32 studies; 860 infants) demonstrated that MR spectroscopy was a better diagnostic tool than conventional MRI [77, 78]. Ratios of Lac/choline in basal nuclei [20] and Lac/NAA accurately predicted adverse neurodevelopmental outcome at 1 year with high specificity and predictive value. [79]. Very early peaks in lactate can normalize; however, the persistence of high lactate in brain is associated with poor outcome [23, 56] (Table 2).

A recent high resolution ^1H -MRS provided new insights into injury and information about the differences in brain in animals treated with hypothermia and normothermia after HI [80]. Biomarkers related to the differential injury pattern were identified in CD1 mice with right carotid artery occlusion and HI at postnatal day (PND) 7, and identified metabolites that distinguished between brains less damaged and more damaged after HI [80]. Changes in malate and aspartate are particularly relevant to metabolism since they suggest impairment in the activity of the malate-aspartate shuttle, which is essential for transferring reducing equivalents from the cytosol to the mitochondria to be used for energy [80, 81].

Studies using ^{13}C -NMR spectroscopy are a powerful tool to determine overall energy metabolism, neurotransmitter synthesis, alterations in cell specific metabolic pathways and neuronal-glial interactions. Morken et al. [14] used ^{13}C -NMR to determine the differences in metabolism in normal neonatal and adult brain (Table 1). To date ^{13}C -NMR has not been used clinically in infants; however, it was recently used in animal studies to determine alterations in specific metabolic pathways following HI [82, 83]. Morken et al. [83] using the clinically relevant carotid artery ligation and hypoxia in PND 7 rat pup (Rice Vannucci model [84]) showed that following HI metabolism via the pentose phosphate pathway (PPP) was reduced bilaterally and metabolism via pyruvate carboxylase (PC) was reduced in the ipsilateral (hypoxic-ischemic) side of brain (Table 2). The PPP pathway is particularly high in developing brain to provide precursors for nucleotide formation, and the NADPH for lipid synthesis and for maintaining reduced glutathione [14]. Thus, a significant decrease in metabolism via this pathway can explain, in part, the decreased brain volume, white matter abnormalities and susceptibility to oxidative stress after HI.

Morken et al. [82] found that metabolism via the pyruvate carboxylase pathway in astrocytes was decreased after HI. This pathway has the essential role of adding net carbons to the TCA cycle (anaplerosis) and provides substrate in the form of glutamine to neurons to replenish carbons in the neuronal TCA cycle, since intermediates are continuously drained from the cycle for synthesis of glutamate and GABA [1, 85] Neonatal HI led to a prolonged depression in mitochondrial metabolism [82]. Mitochondrial metabolism was decreased in

the ipsilateral side at 6 hours post HI and was reduced in neurons but not in astrocytes in the contralateral side [82]. This study provided new insight into sex differences since male pups had lower astrocytic mitochondrial metabolism than females immediately after HI; whereas, mitochondrial metabolism was reduced longer in females and in both neurons and astrocytes [82]. (See Table 2 for details).

Metabolic Alterations After Pediatric Traumatic Brain Injury

A number of adult clinical studies have correlated the extent of metabolic change seen by $^1\text{H-MRS}$ with the severity of injury and neurologic outcome after TBI [52, 54]. After TBI, dramatic reductions in NAA are often observed and correlate with either neuronal cell loss and/or impaired neuronal energy metabolism [55]. Reductions in NAA or in NAA/Creatine and NAA/Choline ratios have been shown to correlate with greater injury severity and worse neurological outcomes after pediatric TBI [63, 86].

Lactate presence in remote (uninjured) areas of the occipital cortex after TBI in children is strongly associated with poor neurological outcome [86]. Multiple studies have reported the strong association between lactate peaks on $^1\text{H-MRS}$ and poor long-term neurological outcome (up to several years) after pediatric TBI [63, 86–88] (Table 2). More recently, this association has also been observed in pediatric victims of abusive head trauma, with infants that show elevated lactate on $^1\text{H-MRS}$ having worse early neurological outcome [89]. These investigators suggested that lactate presence is more common after non-accidental TBI in children than in accidental TBI [90, 91], and that the lactate peaks could represent either primary injury or secondary hypoxic-ischemic injury [89, 90]. Importantly, using a combination of $^1\text{H-MRS}$ metabolites may provide even greater predictive value in both accidental and non-accidental pediatric TBI. For example, in a series of 90 infants who had confirmed non-accidental TBI, a logistic regression model that used the combination of initial Glasgow Coma Score (GCS), presence of retinal hemorrhages, and lactate and NAA values on spectroscopy, was able to predict poor neurologic outcome in 100% of the cases [90]. In another study that included both accidental and non-accidental TBI, $^1\text{H-MRS}$ changes were more predictive of outcomes than clinical findings [88]. One of the few studies to compare $^1\text{H-MRS}$ metabolites with a detailed panel of intelligence and neuropsychologic testing found that the NAA/creatine and choline/creatine ratio, and presence of lactate were predictive of long-term cognitive outcome [88].

Preclinical studies using $^1\text{H-MRS}$ in TBI models offer several potential advantages, such as the ability to obtain data very early (<4h) after injury in order to define the time course of post-traumatic metabolic dysfunction. In clinical studies, the average time to obtain the first $^1\text{H-MRS}$ imaging is ~1 week, often due to the instability of children after moderate to severe TBI, limiting the ability to obtain lengthy MRI/MRS. Using $^1\text{H-MRS}$ in preclinical studies, with both early and serial imaging, will allow testing of neuroprotective strategies aimed at reducing cerebral energy failure after TBI. However, there are very few studies using this approach in pediatric TBI models. Casey et al. [92] used a model of focal TBI (controlled cortical impact, CCI) in immature rats to evaluate spectroscopic changes at 4h, 24h and 7d after injury. The ipsilateral (injured) hemisphere showed early (4h, 24h) increases in lactate/creatine ratios, and delayed (24h, 7d) decreases in NAA/creatine ratios,

with significant decreases in the NAA/lactate ratio at all times studied, in this model of developmental TBI (Table 2). The metabolic alterations occurred early (4 hrs) and prior to significant cell death demonstrating potentially reversible alterations of energy metabolism. Another study used both ^1H and phosphorus (^{31}P) NMR spectroscopy to evaluate neurochemical changes and test the effect of a ketogenic diet on brain metabolism after CCI in juvenile (PND 35) and adult rats [93]. The results showed that initial alterations in brain metabolism were seen earlier (6h) in adult rats than in juvenile rats (24h). Furthermore, the ketogenic diet significantly increased NAA and reduced lactate levels, and improved ATP, creatine and phosphocreatine levels at 24h after TBI in only in the juvenile rats. In a model of more diffuse injury (fluid percussion injury, FPI), investigators used ^{31}P MR spectroscopy at 4h after TBI in immature (PND 7, PND 14, PND 21) and adult rats [94]. In contrast to the finding in adult rats, in the immature rats, there were no significant changes in the ^{31}P MR spectra, which showed relatively normal pH, intracellular free magnesium (iMg) and phosphocreatine/inorganic phosphate (PCr/Pi) ratios at an early time point (4 hrs) after TBI. However, no studies to date have determined these metabolites at later time points after injury. In summary, although there are limited studies using ^1H -MRS in pediatric TBI animal models, the results show the translational potential for utilizing this technique to both define the timeline and degree of metabolic dysfunction after injury, and to evaluate the efficacy of novel neuroprotective strategies targeting metabolic rescue.

To date ^{13}C -NMR has been employed in limited number of preclinical studies of TBI and the majority of these studies were performed in adult animals [69]. Our group used a model of moderate-to-severe brain trauma (CCI) in PND 21–22 day old rats and assessed oxidative glucose metabolism at between 5 and 6 hrs after TBI. Oxidative glucose metabolism via pyruvate dehydrogenase was delayed in both injured and contralateral sides of the brain compared to sham animals, and there was delayed hypermetabolism of glutamate, glutamine and GABA in both sides of injured brain [68]; (Table 2). These findings significantly differ from ^{13}C -NMR in studies adult animals which did not find any differences in oxidative glucose metabolism in glutamatergic neurons in CCI-TBI [95]. Using a fluid percussion model of diffuse brain TBI, in adult rats Bartnik and colleagues [96] demonstrated decreased oxidative glucose metabolism in both astrocytes and neurons as early as 3.5 hrs post TBI. Both adult and immature brain TBI studies demonstrate that in general oxidative metabolism at 24hrs post TBI was comparable to sham operated animals [95–97]. However, the only differences at 24 hr post TBI found in the studies were age specific with decrease ^{13}C label incorporation into glutamine in adult brains, and decreased ^{13}C label incorporation into glutamate in immature brain. These differences may reflect differential cell-specific alterations in response to injury. Additional studies employing multiple ^{13}C -labeled substrates will be particularly useful for further delineating alterations in neuronal and glial metabolic pathways after TBI in developing brain

Alternative Substrates and Metabolic Modifiers in Brain Injury Models

A number of studies have tested the potential of alternative energy substrates and modulators of metabolism for preventing injury and improving metabolic and functional outcomes. Compounds that improve brain function and/or decrease injury volume when administered after injury are the logical therapeutic approaches. Treatment after injury with creatine

monohydrate [98], acetyl-L-carnitine [99], or ketogenic diets [100] have led to improved locomotor and/or cognitive function in young rodents after brain injury (See Table 3). Compounds that can be metabolized for energy in brain, including ketones [93, 101], acetyl-L-carnitine [102], and triheptanoin [103] can lead to improved energy status. Therapy with branched chain amino acids (BCAA) after fluid percussion TBI improved synaptic efficiency and cognitive performance in adult mice presumably by normalizing brain levels of these amino acids which have a role in glutamate metabolism [104]. BCAA therapy as well as triheptanoin which provides anaplerotic substrates to brain and can decrease seizure activity [103, 105] also appear to be potentially useful treatments for pediatric brain injury. A recent study [148] using an electron scavenger specifically targeted to neuronal mitochondrial (XJB-5-131-- a hemigramicidin-nitroxide) demonstrated that this compound prevented mitochondrial cardiolipin oxidation and caspase activation. This therapy decreased neuronal death, behavioral deficits and cortical lesion volume in PND 17 rats after CCI-TBI.

Conclusion

Clinical studies using ^1H -MRS in infants and children have greatly increased the knowledge of temporal and regional changes in brain after injury and the relationship of energy failure to neurologic outcome. Advances in imaging techniques are leading to a better understanding of specific alterations that occur subsequent to prematurity, neonatal and childhood injury including alterations in resting state and brain connectivity. Animal studies have led to an increased understanding of the mechanisms leading to both acute and ongoing injury in developing brain. These include alterations in metabolism via neuronal and glial specific pathways in brain, changes in the expression, level and activity of key proteins involved in development, metabolism and signaling pathways, and the extent of oxidative stress in specific brain injury models. However, there are still many gaps in knowledge including a lack of sufficiently detailed information about temporal alterations in brain energetics and metabolism, the effects of age at time of injury (prenatal, neonatal, during synaptogenesis and rapid myelination or at the peak of myelination), and the effects of diet before, during and after injury.

Our understanding of energy metabolism in developing brain stems from studies of temporal changes in transporter levels and function, enzymatic activity, and changes in cell populations and mitochondrial function. In vivo and ex vivo PET and ^{13}C -NMR spectroscopy have greatly increased our knowledge of regional changes during development and metabolism in developing brain. To date there are relatively few ^{13}C -NMR studies of metabolism via cell specific pathways, neurotransmitter synthesis, and neuron \rightarrow astrocyte and astrocyte \rightarrow neuron metabolic trafficking in developing brain. Many newer tools including genetically modified knock-out, knock-in and inducible Cre-mice, BOLD and resting state MRI, proteomic and lipidomic techniques and imaging including matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) to determine regional alterations in metabolites have great potential to increase the understanding of the normal developmental changes in brain metabolism, alterations resulting from injury and effects of therapies.

Future Directions

Additional clinical studies using ^1H -MRS and advanced neuroimaging techniques will lead to increased understanding of the regional, temporal, and functional changes resulting from prematurity, neonatal hypoxia-ischemia and traumatic brain injury in infants and children. Clinical studies that determine brain changes in conjunction with long-term neurological outcome are particularly important for identifying biomarkers associated with functional outcome. The recent identification of metabolites in plasma, including fumaric acid and propanoic acid, that correlate with, and are potential biomarkers for long term functional outcome in a nonhuman primate model of neonatal HIE is very promising [159]. Clinical studies using conventional ^{13}C -NMR spectroscopy or hyperpolarized ^{13}C -NMR would provide much needed information about alterations in metabolic pathways of specific importance to developing brain and the extent of alterations in astrocytes, neurons and the trafficking of metabolites between these cells. Additional preclinical studies using animal models are essential for increasing the understanding of mechanisms of injury and efficacy of neuroprotective therapies.

Acknowledgments

This article does not contain any studies with human participants performed by any of the authors. All animal studies by the authors that are cited in this study were approved by IACUC and performed in compliance with all NIH guidelines for animal research.

Supported in part by NIH grants 5P01 HD016596 (M.C.M.) and K08 NS 069815 (S.S.).

Conflict of interest: None.

Abbreviations used

| | |
|--------------------|---|
| BBB | blood-brain barrier |
| BHB | β -hydroxybutyrate |
| BHBdehase | β -hydroxybutyrate dehydrogenase |
| CCI | controlled cortical impact traumatic brain injury |
| Cho or tCho | total choline |
| Cr or tCr | total creatine |
| Gln | glutamine |
| Glu | glutamate |
| Glx | glutamate and glutamine |
| GPC | glycerophosphocholine |
| HI | hypoxia-ischemia |
| HIE | hypoxic-ischemic encephalopathy |

| | |
|--------------------------|--|
| ¹H-MRS | proton magnetic resonance spectroscopy |
| Lac | lactate |
| MRI | magnetic resonance imaging |
| MRS | magnetic resonance spectroscopy |
| NAA | N-acetylaspartate |
| PC | pyruvate carboxylase |
| PDH | pyruvate dehydrogenase |
| PND | postnatal day |
| PPP | pentose phosphate pathway |
| TBI | traumatic brain injury |

References

1. McKenna, MC.; Dienel, GA.; Sonnewald, U.; Waagepetersen, HS.; Schousboe, A. Energy metabolism of the brain. In: Brady, S.; Siegel, GJ.; Albers, RW.; Price, D., editors. *Basic Neurochemistry: Principles of Molecular, Cellular and Medical Neurobiology*. Academic Press; Burlington: 2012. p. 200-231.
2. Settergren G, Lindblad BS, Persson B. Cerebral blood flow and exchange of oxygen, glucose, ketone bodies, lactate, pyruvate and amino acids in infants. *Acta Paediatr Scand*. 1976; 65:343–53. [PubMed: 5840]
3. Chugani HT, Phelps ME. Maturation changes in cerebral function in infants determined by 18FDG positron emission tomography. *Science*. 1986; 231:840–3. [PubMed: 3945811]
4. Takahashi T, Shirane R, Sato S, Yoshimoto T. Developmental changes of cerebral blood flow and oxygen metabolism in children. *AJNR Am J Neuroradiol*. 1999; 20:917–22. [PubMed: 10369366]
5. Nehlig A. Brain uptake and metabolism of ketone bodies in animal models. *Prostaglandins Leukot Essent Fatty Acids*. 2004; 70:265–75. [PubMed: 14769485]
6. Nehlig A. Cerebral energy metabolism, glucose transport and blood flow: changes with maturation and adaptation to hypoglycaemia. *Diabetes Metab*. 1997; 23:18–29. [PubMed: 9059763]
7. Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO. Cerebral glucose transport and metabolism in preterm human infants. *J Cereb Blood Flow Metab*. 1998; 18:632–8. [PubMed: 9626187]
8. Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. *Ann Neurol*. 1987; 22:487–97. [PubMed: 3501693]
9. Vannucci SJ, Simpson IA. Developmental switch in brain nutrient transporter expression in the rat. *Am J Physiol Endocrinol Metab*. 2003; 285:E1127–34. [PubMed: 14534079]
10. Brekke E, Morken TS, Sonnewald U. Glucose metabolism and astrocyte-neuron interactions in the neonatal brain. *Neurochem Int*. 2015
11. Buerstatte CR, Behar KL, Novotny EJ, Lai JC. Brain regional development of the activity of alpha-ketoglutarate dehydrogenase complex in the rat. *Brain Res Dev Brain Res*. 2000; 125:139–45. [PubMed: 11154769]
12. Novotny EJ Jr, Ariyan C, Mason GF, O'Reilly J, Haddad GG, Behar KL. Differential increase in cerebral cortical glucose oxidative metabolism during rat postnatal development is greater in vivo than in vitro. *Brain Res*. 2001; 888:193–202. [PubMed: 11150475]
13. Chowdhury GM, Patel AB, Mason GF, Rothman DL, Behar KL. Glutamatergic and GABAergic neurotransmitter cycling and energy metabolism in rat cerebral cortex during postnatal development. *J Cereb Blood Flow Metab*. 2007; 27:1895–907. [PubMed: 17440492]

14. Morken TS, Brekke E, Haberg A, Wideroe M, Brubakk AM, Sonnewald U. Neuron-astrocyte interactions, pyruvate carboxylation and the pentose phosphate pathway in the neonatal rat brain. *Neurochem Res.* 2013; 39:556–69. [PubMed: 23504293]
15. Dukhande VV, Isaac AO, Chatterji T, Lai JC. Reduced glutathione regenerating enzymes undergo developmental decline and sexual dimorphism in the rat cerebral cortex. *Brain Res.* 2009; 1286:19–24. [PubMed: 19450567]
16. Shankaran S, Pappas A, McDonald SA, Vohr BR, Hintz SR, Yolton K, Gustafson KE, Leach TM, Green C, Bara R, Petrie Huitema CM, Ehrenkranz RA, Tyson JE, Das A, Hammond J, Peralta-Carcelen M, Evans PW, Heyne RJ, Wilson-Costello DE, Vaucher YE, Bauer CR, Dusick AM, Adams-Chapman I, Goldstein RF, Guillet R, Papile LA, Higgins RD. Childhood outcomes after hypothermia for neonatal encephalopathy. *N Engl J Med.* 2012; 366:2085–92. [PubMed: 22646631]
17. Yeates KO, Swift E, Taylor HG, Wade SL, Drotar D, Stancin T, Minich N. Short- and long-term social outcomes following pediatric traumatic brain injury. *J Int Neuropsychol Soc.* 2004; 10:412–26. [PubMed: 15147599]
18. Wechsler B, Kim H, Gallagher PR, DiScala C, Stineman MG. Functional status after childhood traumatic brain injury. *J Trauma.* 2005; 58:940–9. discussion 950. [PubMed: 15920407]
19. Giza CC, Kolb B, Harris NG, Asarnow RF, Prins ML. Hitting a moving target: Basic mechanisms of recovery from acquired developmental brain injury. *Dev Neurorehabil.* 2009; 12:255–68. [PubMed: 19956795]
20. Enns GM, Barkovich AJ, Rosenblatt DS, Fredrick DR, Weisiger K, Ohnstad C, Packman S. Progressive neurological deterioration and MRI changes in cblC methylmalonic acidemia treated with hydroxocobalamin. *J Inher Metab Dis.* 1999; 22:599–607. [PubMed: 10399092]
21. Shanmugalingam S, Thornton JS, Iwata O, Bainbridge A, O'Brien FE, Priest AN, Ordidge RJ, Cady EB, Wyatt JS, Robertson NJ. Comparative prognostic utilities of early quantitative magnetic resonance imaging spin-spin relaxometry and proton magnetic resonance spectroscopy in neonatal encephalopathy. *Pediatrics.* 2006; 118:1467–77. [PubMed: 17015537]
22. Goergen SK, Ang H, Wong F, Carse EA, Charlton M, Evans R, Whiteley G, Clark J, Shipp D, Jolley D, Paul E, Cheong JL. Early MRI in term infants with perinatal hypoxic-ischaemic brain injury: interobserver agreement and MRI predictors of outcome at 2 years. *Clin Radiol.* 2014; 69:72–81. [PubMed: 24210250]
23. Cady EB. Magnetic resonance spectroscopy in neonatal hypoxic-ischaemic insults. *Childs Nerv Syst.* 2001; 17:145–9. [PubMed: 11305767]
24. Perlman JM. Intervention strategies for neonatal hypoxic-ischemic cerebral injury. *Clin Ther.* 2006; 28:1353–65. [PubMed: 17062309]
25. Prins ML, Matsumoto J. Metabolic Response of Pediatric Traumatic Brain Injury. *J Child Neurol.*
26. Fatemi A, Wilson MA, Johnston MV. Hypoxic-ischemic encephalopathy in the term infant. *Clin Perinatol.* 2009; 36:835–58. vii. [PubMed: 19944838]
27. Kochanek PM, Clark RS, Ruppel RA, Adelson PD, Bell MJ, Whalen MJ, Robertson CL, Satchell MA, Seidberg NA, Marion DW, Jenkins LW. Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. *Pediatr Crit Care Med.* 2000; 1:4–19. [PubMed: 12813280]
28. Bayir H, Adelson PD, Wisniewski SR, Shore P, Lai Y, Brown D, Janesko-Feldman KL, Kagan VE, Kochanek PM. Therapeutic hypothermia preserves antioxidant defenses after severe traumatic brain injury in infants and children. *Crit Care Med.* 2009; 37:689–95. [PubMed: 19114918]
29. Salmaso N, Jablonska B, Scafidi J, Vaccarino FM, Gallo V. Neurobiology of premature brain injury. *Nat Neurosci.* 2014; 17:341–6. [PubMed: 24569830]
30. Bluml S, Wisnowski JL, Nelson MD Jr, Paquette L, Panigrahy A. Metabolic maturation of white matter is altered in preterm infants. *PLoS One.* 2014; 9:e85829. [PubMed: 24465731]
31. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet.* 2012; 379:2162–72. [PubMed: 22682464]

32. Kinney HC. The near-term (late preterm) human brain and risk for periventricular leukomalacia: a review. *Semin Perinatol.* 2006; 30:81–8. [PubMed: 16731282]
33. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet.* 2008; 371:261–9. [PubMed: 18207020]
34. Thornberg E, Thiringer K, Odeback A, Milsom I. Birth asphyxia: incidence, clinical course and outcome in a Swedish population. *Acta Paediatr.* 1995; 84:927–32. [PubMed: 7488819]
35. Levene ML, Kornberg J, Williams TH. The incidence and severity of post-asphyxial encephalopathy in full-term infants. *Early Hum Dev.* 1985; 11:21–6. [PubMed: 4006822]
36. Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. *Am J Obstet Gynecol.* 2008; 199:587–95. [PubMed: 19084096]
37. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. *Early Hum Dev.* 2010; 86:329–38. [PubMed: 20554402]
38. Robertson CM, Finer NN, Grace MG. School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term. *J Pediatr.* 1989; 114:753–60. [PubMed: 2469789]
39. Dixon G, Badawi N, Kurinczuk JJ, Keogh JM, Silburn SR, Zubrick SR, Stanley FJ. Early developmental outcomes after newborn encephalopathy. *Pediatrics.* 2002; 109:26–33. [PubMed: 11773538]
40. WHO. Table 2. Infant Deaths. World Health Organization; 2005.
41. Inder T, Huppi PS, Zientara GP, Maier SE, Jolesz FA, di Salvo D, Robertson R, Barnes PD, Volpe JJ. Early detection of periventricular leukomalacia by diffusion-weighted magnetic resonance imaging techniques. *J Pediatr.* 1999; 134:631–4. [PubMed: 10228300]
42. Inder TE, Huppi PS, Warfield S, Kikinis R, Zientara GP, Barnes PD, Jolesz F, Volpe JJ. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. *Ann Neurol.* 1999; 46:755–60. [PubMed: 10553993]
43. Higgins RD, Raju T, Edwards AD, Azzopardi DV, Bose CL, Clark RH, Ferriero DM, Guillet R, Gunn AJ, Hagberg H, Hirtz D, Inder TE, Jacobs SE, Jenkins D, Juul S, Laptook AR, Lucey JF, Maze M, Palmer C, Papile L, Pfister RH, Robertson NJ, Rutherford M, Shankaran S, Silverstein FS, Soll RF, Thoresen M, Walsh WF. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. *J Pediatr.* 2011; 159:851–858. e1. [PubMed: 21875719]
44. Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev.* 2007;CD003311. [PubMed: 17943788]
45. Massaro AN, Murthy K, Zaniletti I, Cook N, DiGeronimo R, Dizon M, Hamrick SE, McKay VJ, Natarajan G, Rao R, Smith D, Telesco R, Wadhawan R, Asselin JM, Durand DJ, Evans JR, Dykes F, Reber KM, Padula MA, Pallotto EK, Short BL, Mathur AM. Short-term outcomes after perinatal hypoxic ischemic encephalopathy: a report from the Children’s Hospitals Neonatal Consortium HIE focus group. *J Perinatol.* 2015; 35:290–6. [PubMed: 25393081]
46. Faul, M.; Xu, L.; Wald, MM.; Coronado, VG. *Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002–2006.* Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
47. Giza CC, Mink RB, Madikians A. Pediatric traumatic brain injury: not just little adults. *Curr Opin Crit Care.* 2007; 13:143–52. [PubMed: 17327734]
48. Ryan NP, Anderson V, Godfrey C, Beauchamp MH, Coleman L, Eren S, Rosema S, Taylor K, Catroppa C. Predictors of very-long-term sociocognitive function after pediatric traumatic brain injury: evidence for the vulnerability of the immature “social brain”. *J Neurotrauma.* 2014; 31:649–57. [PubMed: 24147615]
49. Catroppa C, Godfrey C, Rosenfeld JV, Hearps SS, Anderson VA. Functional recovery ten years after pediatric traumatic brain injury: outcomes and predictors. *J Neurotrauma.* 2012; 29:2539–47. [PubMed: 22846066]
50. Babikian T, Asarnow R. Neurocognitive outcomes and recovery after pediatric TBI: meta-analytic review of the literature. *Neuropsychology.* 2009; 23:283–96. [PubMed: 19413443]
51. Kendall GS, Melbourne A, Johnson S, Price D, Bainbridge A, Gunny R, Huertas-Ceballos A, Cady EB, Ourselin S, Marlow N, Robertson NJ. White matter NAA/Cho and Cho/Cr ratios at MR

- spectroscopy are predictive of motor outcome in preterm infants. *Radiology*. 2014; 271:230–8. [PubMed: 24475798]
52. Garnett MR, Blamire AM, Corkill RG, Cadoux-Hudson TA, Rajagopalan B, Styles P. Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. *Brain*. 2000; 123(Pt 10):2046–54. [PubMed: 11004122]
 53. Holshouser BA, Tong KA, Ashwal S. Proton MR spectroscopic imaging depicts diffuse axonal injury in children with traumatic brain injury. *AJNR Am J Neuroradiol*. 2005; 26:1276–85. [PubMed: 15891197]
 54. Brooks WM, Friedman SD, Gasparovic C. Magnetic resonance spectroscopy in traumatic brain injury. *J Head Trauma Rehabil*. 2001; 16:149–64. [PubMed: 11275576]
 55. Ashwal S, Tong KA, Ghosh N, Bartnik-Olson B, Holshouser BA. Application of advanced neuroimaging modalities in pediatric traumatic brain injury. *J Child Neurol*. 2014; 29:1704–17. [PubMed: 24958007]
 56. Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dincer A, Dydak U, Emir UE, Frahm J, Gonzalez RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Huppi PS, Hurd RE, Kantarci K, Klomp DW, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjanska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJ, Ratai EM, Ross BD, Scheenen TW, Schuster C, Smith IC, Soher BJ, Tkac I, Vigneron DB, Kauppinen RA. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology*. 2014; 270:658–79. [PubMed: 24568703]
 57. Cady EB, Penrice J, Amess PN, Lorek A, Wylezinska M, Aldridge RF, Franconi F, Wyatt JS, Reynolds EO. Lactate, N-acetylaspartate, choline and creatine concentrations, and spin-spin relaxation in thalamic and occipito-parietal regions of developing human brain. *Magn Reson Med*. 1996; 36:878–86. [PubMed: 8946353]
 58. Cheong JL, Cady EB, Penrice J, Wyatt JS, Cox IJ, Robertson NJ. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. *AJNR Am J Neuroradiol*. 2006; 27:1546–54. [PubMed: 16908578]
 59. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. *Neurochem Res*. 2014; 39:1–36. [PubMed: 24258018]
 60. Peltier J, O'Neill A, Schaffer DV. PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. *Dev Neurobiol*. 2007; 67:1348–61. [PubMed: 17638387]
 61. Sanchez S, Jimenez C, Carrera AC, Diaz-Nido J, Avila J, Wandosell F. A cAMP-activated pathway, including PKA and PI3K, regulates neuronal differentiation. *Neurochem Int*. 2004; 44:231–42. [PubMed: 14602086]
 62. Kreis R, Hofmann L, Kuhlmann B, Boesch C, Bossi E, Huppi PS. Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. *Magn Reson Med*. 2002; 48:949–58. [PubMed: 12465103]
 63. Holshouser BA, Ashwal S, Luh GY, Shu S, Kahlon S, Auld KL, Tomasi LG, Perkin RM, Hinshaw DB Jr. Proton MR spectroscopy after acute central nervous system injury: outcome prediction in neonates, infants, and children. *Radiology*. 1997; 202:487–96. [PubMed: 9015079]
 64. McLean MA, Woermann FG, Barker GJ, Duncan JS. Quantitative analysis of short echo time (1)H-MRSI of cerebral gray and white matter. *Magn Reson Med*. 2000; 44:401–11. [PubMed: 10975892]
 65. Horska A, Kaufmann WE, Brant LJ, Naidu S, Harris JC, Barker PB. In vivo quantitative proton MRSI study of brain development from childhood to adolescence. *J Magn Reson Imaging*. 2002; 15:137–43. [PubMed: 11836768]
 66. Sonnewald U, Kondziella D. Neuronal glial interaction in different neurological diseases studied by ex vivo 13C NMR spectroscopy. *NMR Biomed*. 2003; 16:424–9. [PubMed: 14679504]
 67. Bartnik BL, Lee SM, Hovda DA, Sutton RL. The fate of glucose during the period of decreased metabolism after fluid percussion injury: a 13C NMR study. *J Neurotrauma*. 2007; 24:1079–92. [PubMed: 17610349]

68. Scafidi S, O'Brien J, Hopkins I, Robertson C, Fiskum G, McKenna M. Delayed cerebral oxidative glucose metabolism after traumatic brain injury in young rats. *J Neurochem*. 2009; 109(Suppl 1): 189–97. [PubMed: 19393027]
69. Bartnik-Olson BL, Harris NG, Shijo K, Sutton RL. Insights into the metabolic response to traumatic brain injury as revealed by (13)C NMR spectroscopy. *Front Neuroenergetics*. 2013; 5:8. [PubMed: 24109452]
70. Ball G, Boardman JP, Rueckert D, Aljabar P, Arichi T, Merchant N, Gousias IS, Edwards AD, Counsell SJ. The effect of preterm birth on thalamic and cortical development. *Cereb Cortex*. 2012; 22:1016–24. [PubMed: 21772018]
71. Hart AR, Smith MF, Whitby EH, Alladi S, Wilkinson S, Paley MN, Griffiths PD. Diffusion-weighted imaging and magnetic resonance proton spectroscopy following preterm birth. *Clin Radiol*. 2014; 69:870–9. [PubMed: 24935906]
72. Scafidi J, Hammond TR, Scafidi S, Ritter J, Jablonska B, Roncal M, Szigeti-Buck K, Coman D, Huang Y, McCarter RJ Jr, Hyder F, Horvath TL, Gallo V. Intranasal epidermal growth factor treatment rescues neonatal brain injury. *Nature*. 2014; 506:230–4. [PubMed: 24390343]
73. Kwon SH, Scheinost D, Lacadie C, Benjamin J, Myers EH, Qiu M, Schneider KC, Rothman DL, Constable RT, Ment LR. GABA, resting-state connectivity and the developing brain. *Neonatology*. 2014; 106:149–55. [PubMed: 24970028]
74. Smyser CD, Kidokoro H, Inder TE. Magnetic resonance imaging of the brain at term equivalent age in extremely premature neonates: to scan or not to scan? *J Paediatr Child Health*. 48:794–800. [PubMed: 22970674]
75. Wisnowski JL, Bluml S, Paquette L, Zelinski E, Nelson MD Jr, Painter MJ, Damasio H, Gilles F, Panigrahy A. Altered glutamatergic metabolism associated with punctate white matter lesions in preterm infants. *PLoS One*. 2013; 8:e56880. [PubMed: 23468888]
76. Bapat R, Narayana PA, Zhou Y, Parikh NA. Magnetic resonance spectroscopy at term-equivalent age in extremely preterm infants: association with cognitive and language development. *Pediatr Neurol*. 2014; 51:53–9. [PubMed: 24938140]
77. Thayyil S, Chandrasekaran M, Taylor A, Bainbridge A, Cady EB, Chong WK, Murad S, Omar RZ, Robertson NJ. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. *Pediatrics*. 2010; 125:e382–95. [PubMed: 20083516]
78. De Vis JB, Hendrikse J, Petersen ET, de Vries LS, van Bel F, Alderliesten T, Negro S, Groenendaal F, Benders MJNL. Arterial spin-labelling perfusion MRI and outcome in neonates with hypoxic-ischemic encephalopathy. *Eur Radiol*. 2015; 25:113–121. [PubMed: 25097129]
79. Amess PN, Penrice J, Wylezinska M, Lorek A, Townsend J, Wyatt JS, Amiel-Tison C, Cady EB, Stewart A. Early brain proton magnetic resonance spectroscopy and neonatal neurology related to neurodevelopmental outcome at 1 year in term infants after presumed hypoxic-ischaemic brain injury. *Dev Med Child Neurol*. 1999; 41:436–445. [PubMed: 10454226]
80. Liu J, Sheldon RA, Segal MR, Kelly MJ, Pelton JG, Ferriero DM, James TL, Litt L. 1H nuclear magnetic resonance brain metabolomics in neonatal mice after hypoxia-ischemia distinguished normothermic recovery from mild hypothermia recoveries. *Pediatr Res*. 2013; 74:170–9. [PubMed: 23708689]
81. McKenna MC, Waagepetersen HS, Schousboe A, Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. *Biochem Pharmacol*. 2006; 71:399–407. [PubMed: 16368075]
82. Morken TS, Brekke E, Haberg A, Wideroe M, Brubakk AM, Sonnewald U. Altered astrocyte-neuronal interactions after hypoxia-ischemia in the neonatal brain in female and male rats. *Stroke*. 2014; 45:2777–85. [PubMed: 25052323]
83. Brekke EM, Morken TS, Wideroe M, Haberg AK, Brubakk AM, Sonnewald U. The pentose phosphate pathway and pyruvate carboxylation after neonatal hypoxic-ischemic brain injury. *J Cereb Blood Flow Metab*. 2014; 34:724–34. [PubMed: 24496178]
84. Rice JE 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. *Ann Neurol*. 1981; 9:131–41. [PubMed: 7235629]
85. Schousboe A, Scafidi S, Bak LK, Waagepetersen HS, McKenna MC. Glutamate metabolism in the brain focusing on astrocytes. *Adv Neurobiol*. 11:13–30. [PubMed: 25236722]

86. Ashwal S, Holshouser BA, Shu SK, Simmons PL, Perkin RM, Tomasi LG, Knierim DS, Sheridan C, Craig K, Andrews GH, Hinshaw DB. Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury. *Pediatr Neurol.* 2000; 23:114–25. [PubMed: 11020636]
87. Ashwal S, Holshouser BA, Tomasi LG, Shu S, Perkin RM, Nystrom GA, Hinshaw DB Jr. 1H-magnetic resonance spectroscopy-determined cerebral lactate and poor neurological outcomes in children with central nervous system disease. *Ann Neurol.* 1997; 41:470–81. [PubMed: 9124804]
88. Brenner T, Freier MC, Holshouser BA, Burley T, Ashwal S. Predicting neuropsychologic outcome after traumatic brain injury in children. *Pediatr Neurol.* 2003; 28:104–14. [PubMed: 12699860]
89. Makoroff KL, Cecil KM, Care M, Ball WS Jr. Elevated lactate as an early marker of brain injury in inflicted traumatic brain injury. *Pediatr Radiol.* 2005; 35:668–76. [PubMed: 15830194]
90. Aaen GS, Holshouser BA, Sheridan C, Colbert C, McKenney M, Kido D, Ashwal S. Magnetic resonance spectroscopy predicts outcomes for children with nonaccidental trauma. *Pediatrics.* 2010; 125:295–303. [PubMed: 20123781]
91. Hunter JV, Wilde EA, Tong KA, Holshouser BA. Emerging imaging tools for use with traumatic brain injury research. *J Neurotrauma.* 2012; 29:654–71. [PubMed: 21787167]
92. Casey PA, McKenna MC, Fiskum G, Saraswati M, Robertson CL. Early and sustained alterations in cerebral metabolism after traumatic brain injury in immature rats. *J Neurotrauma.* 2008; 25:603–14. [PubMed: 18454682]
93. Deng-Bryant Y, Prins ML, Hovda DA, Harris NG. Ketogenic diet prevents alterations in brain metabolism in young but not adult rats after traumatic brain injury. *J Neurotrauma.* 2012; 28:1813–25. [PubMed: 21635175]
94. Cernak I, Chang T, Ahmed FA, Cruz MI, Vink R, Stoica B, Faden AI. Pathophysiological response to experimental diffuse brain trauma differs as a function of developmental age. *Dev Neurosci.* 2010; 32:442–53. [PubMed: 20948187]
95. Bartnik BL, Sutton RL, Fukushima M, Harris NG, Hovda DA, Lee SM. Upregulation of pentose phosphate pathway and preservation of tricarboxylic acid cycle flux after experimental brain injury. *J Neurotrauma.* 2005; 22:1052–65. [PubMed: 16238483]
96. Bartnik BL, Hovda DA, Lee PW. Glucose metabolism after traumatic brain injury: estimation of pyruvate carboxylase and pyruvate dehydrogenase flux by mass isotopomer analysis. *J Neurotrauma.* 2007; 24:181–94. [PubMed: 17263682]
97. Robertson CL, Saraswati M, Scafidi S, Fiskum G, Casey P, McKenna MC. Cerebral glucose metabolism in an immature rat model of pediatric traumatic brain injury. *J Neurotrauma.* 2013; 30:2066–72. [PubMed: 24032394]
98. Adcock KH, Nedelcu J, Loenneker T, Martin E, Wallimann T, Wagner BP. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. *Dev Neurosci.* 2002; 24:382–8. [PubMed: 12640176]
99. Scafidi S, Racz J, Hazelton J, McKenna MC, Fiskum G. Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain. *Dev Neurosci.* 2010; 32:480–7. [PubMed: 21228558]
100. Prins ML, Fujima LS, Hovda DA. Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury. *J Neurosci Res.* 2005; 82:413–20. [PubMed: 16180224]
101. Prins ML, Lee SM, Fujima LS, Hovda DA. Increased cerebral uptake and oxidation of exogenous betaHB improves ATP following traumatic brain injury in adult rats. *J Neurochem.* 2004; 90:666–72. [PubMed: 15255945]
102. Scafidi S, Fiskum G, Lindauer SL, Bamford P, Shi D, Hopkins I, McKenna MC. Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the immature rat brain. *J Neurochem.* 2010; 114:820–31. [PubMed: 20477950]
103. Hadera MG, Smeland OB, McDonald TS, Tan KN, Sonnewald U, Borges K. Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy. *J Neurochem.* 2014; 129:107–19. [PubMed: 24236946]
104. Cole JT, Mitala CM, Kundu S, Verma A, Elkind JA, Nissim I, Cohen AS. Dietary branched chain amino acids ameliorate injury-induced cognitive impairment. *Proc Natl Acad Sci U S A.* 2010; 107:366–71. [PubMed: 19995960]

105. Willis S, Stoll J, Sweetman L, Borges K. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. *Neurobiol Dis.* 2010; 40:565–72. [PubMed: 20691264]
106. Leong SF, Clark JB. Regional enzyme development in rat brain. Enzymes associated with glucose utilization. *Biochem J.* 1984; 218:131–8. [PubMed: 6712609]
107. Dombrowski GJ Jr, Swiatek KR, Chao KL. Lactate, 3-hydroxybutyrate, and glucose as substrates for the early postnatal rat brain. *Neurochem Res.* 1989; 14:667–75. [PubMed: 2779727]
108. Klee CB, Sokoloff L. Changes in D(–)-beta-hydroxybutyric dehydrogenase activity during brain maturation in the rat. *J Biol Chem.* 1967; 242:3880–3. [PubMed: 4382562]
109. Levitsky LL, Fisher DE, Paton JB, Delannoy CW. Fasting plasma levels of glucose, acetoacetate, D-beta-hydroxybutyrate, glycerol, and lactate in the baboon infant: correlation with cerebral uptake of substrates and oxygen. *Pediatr Res.* 1977; 11:298–302. [PubMed: 403503]
110. Settergren G, Lindblad BS, Persson B. Cerebral blood flow and exchange of oxygen, glucose ketone bodies, lactate, pyruvate and amino acids in anesthetized children. *Acta Paediatr Scand.* 1980; 69:457–65. [PubMed: 7446094]
111. Cremer JE, Cunningham VJ, Pardridge WM, Braun LD, Oldendorf WH. Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. *J Neurochem.* 1979; 33:439–45. [PubMed: 469534]
112. Ninfali P, Aluigi G, Pompella A. Postnatal expression of glucose-6-phosphate dehydrogenase in different brain areas. *Neurochem Res.* 1998; 23:1197–204. [PubMed: 9712191]
113. Murthy MR, Rappoport DA. Biochemistry of the Developing Rat Brain. Iii. Mitochondrial Oxidation of Citrate and Isocitrate and Associated Phosphorylation. *Biochim Biophys Acta.* 1963; 74:328–39. [PubMed: 14071577]
114. McKenna MC, Tildon JT, Stevenson JH, Hopkins IB. Energy metabolism in cortical synaptic terminals from weanling and mature rat brain: evidence for multiple compartments of tricarboxylic acid cycle activity. *Dev Neurosci.* 1994; 16:291–300. [PubMed: 7768208]
115. Hawkins RA, Williamson DH, Krebs HA. Ketone-body utilization by adult and suckling rat brain in vivo. *Biochem J.* 1971; 122:13–8. [PubMed: 5124783]
116. Edmond J, Auestad N, Robbins RA, Bergstrom JD. Ketone body metabolism in the neonate: development and the effect of diet. *Fed Proc.* 1985; 44:2359–64. [PubMed: 3884392]
117. Cremer JE. Substrate utilization and brain development. *J Cereb Blood Flow Metab.* 1982; 2:394–407. [PubMed: 6754750]
118. Cremer JE, Braun LD, Oldendorf WH. Changes during development in transport processes of the blood-brain barrier. *Biochim Biophys Acta.* 1976; 448:633–7. [PubMed: 823975]
119. Edmond J. Ketone bodies as precursors of sterols and fatty acids in the developing rat. *J Biol Chem.* 1974; 249:72–80. [PubMed: 4809632]
120. Tildon JT, Cone AL, Cornblath M. Coenzyme A transferase activity in rat brain. *Biochem Biophys Res Commun.* 1971; 43:225–31. [PubMed: 5579946]
121. Page MA, Krebs HA, Williamson DH. Activities of enzymes of ketone-body utilization in brain and other tissues of suckling rats. *Biochem J.* 1971; 121:49–53. [PubMed: 5116556]
122. Booth RF, Patel TB, Clark JB. The development of enzymes of energy metabolism in the brain of a precocial (guinea pig) and non-precocial (rat) species. *J Neurochem.* 1980; 34:17–25. [PubMed: 6108983]
123. Swiatek KR, Dombrowski GJ Jr, Chao KL. The metabolism of D- and L-3-hydroxybutyrate in developing rat brain. *Biochem Med.* 1984; 31:332–46. [PubMed: 6477538]
124. Cremer JE. Incorporation of label from D- -hydroxy(¹⁴C)butyrate and (3- ¹⁴C)acetoacetate into amino acids in rat brain in vivo. *Biochem J.* 1971; 122:135–8. [PubMed: 5117566]
125. Tildon JT, Cornblath M. Succinyl-CoA: 3-ketoacid CoA-transferase deficiency. A cause for ketoacidosis in infancy. *J Clin Invest.* 1972; 51:493–8. [PubMed: 4258782]
126. Chowdhury GM, Jiang L, Rothman DL, Behar KL. The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo. *J Cereb Blood Flow Metab.* 2014; 34:1233–42. [PubMed: 24780902]
127. Edmond J, Higa TA, Korsak RA, Bergner EA, Lee WN. Fatty acid transport and utilization for the developing brain. *J Neurochem.* 1998; 70:1227–34. [PubMed: 9489745]

128. Tabata H, Bell JM, Miller JC, Rapoport SI. Incorporation of plasma palmitate into the brain of the rat during development. *Brain Res.* 1986; 394:1–8. [PubMed: 3756528]
129. Innis SM, Sprecher H, Hachey D, Edmond J, Anderson RE. Neonatal polyunsaturated fatty acid metabolism. *Lipids.* 1999; 34:139–49. [PubMed: 10102240]
130. Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by ¹³C nuclear magnetic resonance spectroscopy. *J Neurosci.* 2003; 23:5928–35. [PubMed: 12843297]
131. Leyton J, Drury PJ, Crawford MA. In vivo incorporation of labeled fatty acids in rat liver lipids after oral administration. *Lipids.* 1987; 22:553–8. [PubMed: 3657393]
132. Leyton J, Drury PJ, Crawford MA. Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat. *Br J Nutr.* 1987; 57:383–93. [PubMed: 3109464]
133. Cremer JE. Amino Acid Metabolism in Rat Brain Studied with ¹⁴C-Labelled Glucose. *J Neurochem.* 1964; 11:165–85. [PubMed: 14165154]
134. Van Kooij BJ, Benders MJ, Anbeek P, Van Haastert IC, De Vries LS, Groenendaal F. Cerebellar volume and proton magnetic resonance spectroscopy at term, and neurodevelopment at 2 years of age in preterm infants. *Dev Med Child Neurol.* 2012; 54:260–6. [PubMed: 22211363]
135. Lai JC, White BK, Buerstatte CR, Haddad GG, Novotny EJ Jr, Behar KL. Chronic hypoxia in development selectively alters the activities of key enzymes of glucose oxidative metabolism in brain regions. *Neurochem Res.* 2003; 28:933–40. [PubMed: 12718448]
136. Fatemi A, Wilson MA, Phillips AW, McMahon MT, Zhang J, Smith SA, Arauz EJ, Falahati S, Gummadaavelli A, Bodagala H, Mori S, Johnston MV. In vivo magnetization transfer MRI shows dysmyelination in an ischemic mouse model of periventricular leukomalacia. *J Cereb Blood Flow Metab.* 2011; 31:2009–18. [PubMed: 21540870]
137. Groenendaal F, Veenhoven RH, van der Grond J, Jansen GH, Witkamp TD, de Vries LS. Cerebral lactate and N-acetyl-aspartate/choline ratios in asphyxiated full-term neonates demonstrated in vivo using proton magnetic resonance spectroscopy. *Pediatr Res.* 1994; 35:148–51. [PubMed: 8165047]
138. Hanrahan JD, Cox IJ, Edwards AD, Cowan FM, Sargentoni J, Bell JD, Bryant DJ, Rutherford MA, Azzopardi D. Persistent increases in cerebral lactate concentration after birth asphyxia. *Pediatr Res.* 1998; 44:304–11. [PubMed: 9727705]
139. Angeles DM, Ashwal S, Wycliffe ND, Ebner C, Fayard E, Sowers L, Holshouser BA. Relationship between opioid therapy, tissue-damaging procedures, and brain metabolites as measured by proton MRS in asphyxiated term neonates. *Pediatr Res.* 2007; 61:614–21. [PubMed: 17413864]
140. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. *Nat Genet.* 2003; 35:131–8. [PubMed: 14517540]
141. de Vries MJ, Sival DA, van Doormaal-Stremmelaar EF, Ter Horst HJ. Traumatic perforation of the lamina cribrosa during nasal intubation of a preterm infant. *Pediatrics.* 133:e762–5. [PubMed: 24534399]
142. Zhu W, Zhong W, Qi J, Yin P, Wang C, Chang L. Proton magnetic resonance spectroscopy in neonates with hypoxic-ischemic injury and its prognostic value. *Transl Res.* 2008; 152:225–32. [PubMed: 19010293]
143. Robertson NJ, Lewis RH, Cowan FM, Allsop JM, Counsell SJ, Edwards AD, Cox IJ. Early increases in brain myo-inositol measured by proton magnetic resonance spectroscopy in term infants with neonatal encephalopathy. *Pediatr Res.* 2001; 50:692–700. [PubMed: 11726726]
144. Groenendaal F, Roelants-Van Rijn AM, van Der Grond J, Toet MC, de Vries LS. Glutamate in cerebral tissue of asphyxiated neonates during the first week of life demonstrated in vivo using proton magnetic resonance spectroscopy. *Biol Neonate.* 2001; 79:254–7. [PubMed: 11275661]

145. Vial F, Serriere S, Barantin L, Montharu J, Nadal-Desbarats L, Pourcelot L, Seguin F. A newborn piglet study of moderate hypoxic-ischemic brain injury by 1H-MRS and MRI. *Magn Reson Imaging*. 2004; 22:457–65. [PubMed: 15120164]
146. Maliszka KL, Kozlowski P, Ning G, Bascaramurty S, Tuor UI. Metabolite changes in neonatal rat brain during and after cerebral hypoxia-ischemia: a magnetic resonance spectroscopic imaging study. *NMR Biomed*. 1999; 12:31–8. [PubMed: 10195327]
147. Xu S, Waddell J, Zhu W, Shi D, Marshall AD, McKenna MC, Gullapalli RP. In vivo longitudinal proton magnetic resonance spectroscopy on neonatal hypoxic-ischemic rat brain injury: Neuroprotective effects of acetyl-L-carnitine. *Magn Reson Med*. 2014
148. Babikian T, Prins ML, Cai Y, Barkhoudarian G, Hartonian I, Hovda DA, Giza CC. Molecular and physiological responses to juvenile traumatic brain injury: focus on growth and metabolism. *Dev Neurosci*. 2010; 32:431–41. [PubMed: 21071915]
149. Ashwal S, Holshouser B, Tong K, Serna T, Osterdock R, Gross M, Kido D. Proton MR spectroscopy detected glutamate/glutamine is increased in children with traumatic brain injury. *J Neurotrauma*. 2004; 21:1539–52. [PubMed: 15684647]
150. Ashwal S, Holshouser B, Tong K, Serna T, Osterdock R, Gross M, Kido D. Proton spectroscopy detected myoinositol in children with traumatic brain injury. *Pediatr Res*. 2004; 56:630–8. [PubMed: 15295080]
151. Kochanek AR, Kline AE, Gao WM, Chadha M, Lai Y, Clark RS, Dixon CE, Jenkins LW. Gel-based hippocampal proteomic analysis 2 weeks following traumatic brain injury to immature rats using controlled cortical impact. *Dev Neurosci*. 2006; 28:410–9. [PubMed: 16943664]
152. Robertson CL, Saraswati M, Fiskum G. Mitochondrial dysfunction early after traumatic brain injury in immature rats. *J Neurochem*. 2007; 101:1248–57. [PubMed: 17403141]
153. Ji J, Baart S, Vikulina AS, Clark RS, Anthonymuthu TS, Tyurin VA, Du L, St Croix CM, Tyurina YY, Lewis J, Skoda EM, Kline AE, Kochanek PM, Wipf P, Kagan VE, Bayir H. Deciphering of mitochondrial cardiolipin oxidative signaling in cerebral ischemia-reperfusion. *J Cereb Blood Flow Metab*. 2015; 35:319–28. [PubMed: 25407268]
154. Prins ML, Giza CC. Induction of monocarboxylate transporter 2 expression and ketone transport following traumatic brain injury in juvenile and adult rats. *Dev Neurosci*. 2006; 28:447–56. [PubMed: 16943667]
155. Potts MB, Rola R, Claus CP, Ferriero DM, Fike JR, Noble-Haeusslein LJ. Glutathione peroxidase overexpression does not rescue impaired neurogenesis in the injured immature brain. *J Neurosci Res*. 2009; 87:1848–57. [PubMed: 19170177]
156. Wainwright MS, Mannix MK, Brown J, Stumpf DA. L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats. *Pediatr Res*. 2003; 54:688–95. [PubMed: 12904603]
157. Wainwright MS, Kohli R, Whittington PF, Chace DH. Carnitine treatment inhibits increases in cerebral carnitine esters and glutamate detected by mass spectrometry after hypoxia-ischemia in newborn rats. *Stroke*. 2006; 37:524–30. [PubMed: 16385097]
158. Williams JJ, Mayurasakorn K, Vannucci SJ, Mastropietro C, Bazan NG, Ten VS, Deckelbaum RJ. N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice. *PLoS One*. 8:e56233. [PubMed: 23437099]
159. Chun PT, McPherson RJ, Marney LC, Zangeneh SZ, Parsons BA, Shojaie A, Synovec RE, Juul SE. Serial plasma metabolites following hypoxic-ischemic encephalopathy in a nonhuman primate model. *Dev Neurosci*. 2015; 37:161–171. [PubMed: 25765047]
160. Appelberg KS, Hovda DA, Prins ML. The effects of a ketogenic diet on behavioral outcome after controlled cortical impact injury in the juvenile and adult rat. *J Neurotrauma*. 2009; 26:497–506. [PubMed: 19231995]
161. Ji J, Kline AE, Amoscato A, Samhan-Arias AK, Sparvero LJ, Tyurin VA, Tyurina YY, Fink B, Manole MD, Puccio AM, Okonkwo DO, Cheng JP, Alexander H, Clark RS, Kochanek PM, Wipf P, Kagan VE, Bayir H. Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury. *Nat Neurosci*. 2012; 15:1407–1413. [PubMed: 22922784]

Table 1

Metabolism of substrates in developing versus adult brain

| Substrate | Developing brain compared to adult brain | References |
|----------------|--|---|
| Glucose | <p><u>Overall metabolism/substrate use:</u></p> <ul style="list-style-type: none"> • Glucose oxidation developing \ll adult brain • Glucose uptake can account for 50% or less of cerebral oxygen consumption in the newborn period. (newborn Baboons -- in the first 50 hr of life) • 12 infants (age 11 days-12 months) uptake ~ 1.04 ml/min/mg brain rain tissue in nine anesthetized human infants. <p><u>Transport:</u></p> <ul style="list-style-type: none"> • Glucose uptake developing < adult brain • GLUT 3 developing \ll adult brain • GLUT1 developing < adult brain <p><u>Enzymes:</u></p> <ul style="list-style-type: none"> • Pyruvate dehydrogenase (PDH), citrate synthase, and NAD⁺-linked isocitrate dehydrogenase (ICDH) increase rapidly ~4-5-fold in cortex from birth to PND 20 with adult values reached between 20-40 days; varies increase in fumarase was ~ 3-fold; increases varied by enzyme & brain region • KGDHC activity increases 3-4-fold in brain regions between PND 2-4 and PND 30 • Pentose phosphate pathway (PPP) enzyme glucose 6-phosphate dehydrogenase (reports vary); Cortex: highest at PND5 declined gradually to adult levels at PND 60; • Glucose 6-phosphate dehydrogenase Cortex: PND 5 & PND 10 same and ~ 25% increase at PND 21 • GPDH activity in female > male brain at PND 5, 20 and 60 • NADP⁺-isocitrate dehydrogenase high at birth and decline ~ 50% by PND 30 • Citrate synthase increases ~ fourfold in the first four weeks after birth and remains high in adult brain • 6-phosphogluconate dehydrogenase; Cortex increase ~ 30% between PND5 to peak at PND 10 - 21; decreases ~30% by PND 90; increase in the first few weeks after birth and subsequently decline • Overall PPP activity developing brain > adult <p>Metabolism – specific pathways and cells:</p> <ul style="list-style-type: none"> • Glucose oxidation developing \ll adult brain (PND 7 rat versus 250 g rats) ¹³C-glucose metabolism • Glucose → Acetyl CoA developing brain < adult • Increase in TCA cycle flux from PND which closely parallels increase in KGDHC activity • Rates of TCA cycle flux and neurotransmitter cycling increase at least 3-fold from postnatal day 10 to 30 • Metabolism via pyruvate carboxylase (PC) developing < adult brain • <u>proportion</u> of glucose metabolism to anaplerosis/PDH PND 7 > adult • Ratio of PPP/total glucose metabolism higher in developing brain than adult | <p>[106-108]</p> <p>[109]</p> <p>[110]</p> <p>[111]</p> <p>[9]</p> <p>[9]</p> <p>[106]</p> <p>[11]</p> <p>[15]</p> <p>[112]</p> <p>[15]</p> <p>[113]</p> <p>[10]</p> <p>[112]</p> <p>[10, 14]</p> <p>[14]</p> <p>[14]</p> <p>[12]</p> <p>[13]</p> <p>[14]</p> <p>[14]</p> <p>[14]</p> |

| Substrate | Developing brain compared to adult brain | References |
|--------------------|---|---|
| | <ul style="list-style-type: none"> • More glucose prioritized to PPP & PC in developing versus adult brain • Glutamate transfer from Neurons → Astrocytes P 7 < adult brain • Glutamine transfer from Astrocytes → Glutamatergic Neurons p7 > adult • Glutamine transfer from Astrocytes → GABAergic Neurons p7 < adult • Glucose oxidation in synaptosomes PND 17–18 ~ 66% of adult rate | <p>[14] [14] [14] [14] [114]</p> |
| Ketones | <p><u>Overall metabolism/substrate use:</u></p> <ul style="list-style-type: none"> • Developing > adult brain • Ketone body metabolism supported ~ 48 to 76% of the energy in PND 16–28 rat brain <p><u>Transport:</u></p> <ul style="list-style-type: none"> • MCT1 developing > adult brain • High uptake of BHB into brain in suckling rats • Human infants – uptake of ketone bodies > than adult values reported <p><u>Enzymes:</u></p> <ul style="list-style-type: none"> • Beta hydroxybutyrate dehydrogenase (BHBdehase) enzyme activity in cortex increases 5 fold from birth to PND 25; activity is 3–4-fold higher at PND 15 > mature brain • CoA transferase increase 4–5-fold from birth to PND 20; decreases 4-fold in adult • BHBdehase enzyme activity developing brain > adult brain; similar pattern in most regions <p><u>Metabolism:</u></p> <ul style="list-style-type: none"> • 3-hydroxybutyrate is a preferred substrate for sterol synthesis in developing brain • Oxidation of BHB was higher in synaptosomes from PND 17–18 > adult rat brain • Ketone bodies are incorporated into amino acids in developing brain • Loss of activity in the ketone body metabolizing enzyme CoA transferase lead to developmental disability in human infants • Metabolism of [1,2-¹³C]acetate developing brain < adults • Infused BHB accounted for 62% of neuronal oxidation in awake young adult rats | <p>[9, 115, 116] [115] [9] [115, 117, 118] [2] [108, 115, 119] [108] [120] [106] [120–122] [119] [114, 123] [124] [125] [14] [126]</p> |
| Lactate | <p><u>Transport:</u></p> <ul style="list-style-type: none"> • Cerebral uptake of lactate was observed at birth in newborn Baboons <p><u>Overall metabolism/substrate use:</u></p> <ul style="list-style-type: none"> • 70% of energy was from lactate oxidation in p6 rat brain • synaptosomal lactate oxidation at p17–18 was 20% > adults | <p>[109] [107] [114]</p> |
| Fatty acids | <p><u>Overall metabolism/substrate use:</u></p> | |

| Substrate | Developing brain compared to adult brain | References |
|--------------------|---|---|
| | <ul style="list-style-type: none"> • Developing brain \gg adult brain <p><u>Transport:</u></p> <ul style="list-style-type: none"> • Palmitate uptake into most brain regions increase ~ 2-fold between PND 15-PND 20 in gray and white matter regions; uptake corresponds to the time course of myelination • Palmitate uptake declined 4–5-fold in gray matter and 7–10-fold in white matter by PND 38 days and reached adult levels by 3 months. <p><u>Metabolism:</u></p> <ul style="list-style-type: none"> • The white/gray ratio for palmitate uptake declined significantly between 20 > 38 days & 38 > 90 days of age • Palmitate is incorporated into proteins, lipids including phospholipids, neutral lipids and fatty acids, and gangliosides, and amino acids and TCA cycle intermediates • High rate of synthesis of saturated and monounsaturated fatty acids, such as palmitate, in the PND 6-PND14 developing brain (not taken up intact) • Synthesis of longer chain PUFA is from dietary precursors 18:2ω6 and 18:3ω3 • ¹³C-Octanoate accounted for 20% of total brain oxidative energy production in normal adult rat brain; metabolized in astrocytes > neurons • Whole body fatty acid oxidation high in PND 21 rat pup; oleic acid had highest oxidation rate (the major FA in human milk) | <p>[127]</p> <p>[128]</p> <p>[128]</p> <p>[128]</p> <p>[127]</p> <p>[127]</p> <p>[129]</p> <p>[130]</p> <p>[131, 132]</p> |
| Amino acids | <p><u>Transport:</u></p> <ul style="list-style-type: none"> • Significant cerebral uptakes for histidine and arginine in infants • Amino acids taken up across BBB into developing brain and use in PND 15rat ~ = adult | <p>[2]</p> <p>[133] [118]</p> |

Table 2

Metabolic alterations after injury to developing brain

| Injury Type | Clinical or Models | Metabolic alterations | References |
|---------------------------|--|---|--|
| Premature brain injury | Clinical | <p>¹H spectra MRS and NMR data</p> <ul style="list-style-type: none"> preterm infants with birth weight 500–1500g compared to term neonates born at 37–41 weeks of gestation; decreased concentrations of GABA and glutamate in the frontal cortex in preterm neonates compared to term preterm infants born at 25 weeks of gestation had decreased NAA/Cho in subventricular zone, frontal right cortex and right hippocampus; cerebellar volume was decreased in preterm infants born at 25–31 weeks of gestation; decreased NAA/Cho in cerebellum; | [73] [76] [134] |
| | <p>Models</p> <p>Chronic hypoxia</p> <p>PND 3–11 mice</p> <p>Carotid artery ligation PND 5 mice</p> | <ul style="list-style-type: none"> white matter NAA was decreased at PND 18 and PND 30 mice following chronic hypoxia from PND 3-PND 11; PND10 had increased activity of LDH, no difference was observed in the activity of citrate synthase, alpha-ketoglutarate dehydrogenase; many enzymes altered at PND 30 Ventriculomegaly, thinning of the corpus callosum, decreased myelin basic protein on the side of ligation, | [72] [135] [136] |
| Neonatal Hypoxia Ischemia | Clinical | <p>¹H spectra and MRS and NMR data</p> <ul style="list-style-type: none"> Newborn infants with HI: increased cerebral Lac is an early indication of clinical brain injury Persistence of high Lac is associated with poor outcome Perinatal HI with severe or fatal outcomes had increased Lac, decreased total Cho (tCho) and n-acetylaspartate (NAA) <p>¹H-MRS results and & neurological outcome at 6 months or 1 year:</p> <ul style="list-style-type: none"> Meta-analysis of prognostic accuracy of MR biomarkers and correlation with neurodevelopmental outcome at 1 year (32 studies; 860 infants); Lac/NAA in deep gray matter had an 82% overall pooled sensitivity and 95% specificity and was a better diagnostic tool than conventional MRI. Lac/NAA was most accurate quantitative MR biomarker for prediction of neurological outcome. Poor outcome associated with presence of Lac, lower NAA/Cr & lower NAA/Cho Increased Lac and decreased NAA most common findings in infants with neurological abnormalities at 12 months; highest significance was Lac/choline in basal nuclei. (Mental Development Index of the Bayley Scores of Infant Development at 12 months) Maximal cerebral peak area of Lac/NAA accurately predicted adverse outcome at 1 year Increased Lac and decreased Cr in HIE; mild lesions, Lac/Cr < 0.5, mild to moderate lesion, Lac/Cr 0.5–1.5; severe lesions, Lac/Cr > 1.5 MRS metabolite ratio of Lac/NAA deep grey matter best predictor of adverse outcome Changes in Lac, NAA & Cho in HIE; highest Cho and Lac levels in gray matter differentiated non-survivors from survivors | [56, 137] [23, 138] [23] [77] [63,139] [22] [79] [140] [21] [141] |

| Injury Type | Clinical or Models | Metabolic alterations | References |
|--|--|---|---|
| | <p>Models</p> <p>Piglet</p> <p>PND 7 rat pup</p> <p>PND 7 rat pup</p> <p>PND 7 mouse</p> <p>PND 7 rat pup</p> | <ul style="list-style-type: none"> • Lac/Cr correlated with clinical grading in moderate & severe HIE • Myo-inositol/Cr and Lac/Cr were higher in infants with abnormal MRI and poor outcome • Glx in basal ganglia elevated in severe HIE; Glx/NAA and Glx/Cho ratios higher in severe outcome than in mild-moderate group • Piglet model of HI, increases in Lac/NAA, Lac/tCho and Lac/Cr were observed up to 7 days after injury • PND 7 rat pup; Lac concentration in ipsilateral hemispheres was high and remained high during the first 48 h after injury; NAA in ipsilateral side decreased to $55 \pm 14\%$ during hypoxia, recovered during early post hypoxic period, and decreased to $61 \pm 25\%$ and $41 \pm 28\%$ at 24 and 48 h post HI respectively • PND 7 rat pup (75 min HI) significant reductions in reduced glutathione (GSH), myo-inositol, taurine, and total creatine (tCr) in the ipsilateral hippocampus at 24 hr post HI; no significant changes in cortex of HI pups compared with the controls • PND 7 mouse pups (30 min HI); alterations in formate, acetate, NAA, fumarate, succinate, glutamine, isoleucine, histidine, malate, ascorbate and taurine, differed after hypothermic vs normothermic recovery <p>¹³C-Glucose and acetate metabolism – after H/I in PND 7 rat brain</p> <ul style="list-style-type: none"> • Metabolism via pentose phosphate pathway (PPP) was reduced bilaterally after HI; metabolism via Pyruvate carboxylase (PC) reduced in ipsilateral side • Mitochondrial metabolism decreased in ipsilateral side 6 hours post HI • mitochondrial metabolism reduced in neurons but not in astrocytes in contralateral side • Glutamate transfer from Neurons → Astrocytes increased in the contralateral, but not in ipsilateral side at 0 hour; reduced in both sides at 6 hours after HI. • Glutamine transfer from Astrocytes → Glutamatergic neurons was not altered in both hemispheres • Glutamine transfer from Astrocytes → GABAergic neurons was increased in ipsilateral side immediately after H/I • Metabolism via PC in astrocytes (anaplerosis) decreased after H/I • Partial pyruvate recycling pathway was increased directly after HI. • Male pups had lower astrocytic mitochondrial metabolism than females immediately after HI, • Mitochondrial metabolism was reduced longer in females and in both neurons and astrocytes. | <p>[142]</p> <p>[143]</p> <p>[144]</p> <p>[145]</p> <p>[146]</p> <p>[147]</p> <p>[80]</p> <p>[83]</p> <p>[82]</p> <p>[82]</p> <p>[82]</p> <p>[82]</p> <p>[82]</p> <p>[82]</p> <p>[82]</p> <p>[10]</p> <p>[82]</p> <p>[82]</p> |
| <p>Traumatic brain injury (TBI)</p> | <p>Clinical</p> <p>Models</p> | <p>¹H-MRS</p> <ul style="list-style-type: none"> • Diffuse axonal injury is characterized by decreased NAA/Cr and increased Cho/Cr; NAA/Cr was decreased more in children with poor outcome. • Increased in glutamate following TBI regardless of outcome • Myo-inositol increased after TBI in children and elevated levels correlate to poor neurological outcomes; • Controlled cortical impact (CCI) | <p>[53]</p> <p>[149]</p> <p>[150]</p> |

| Injury Type | Clinical or Models | Metabolic alterations | References |
|-------------|--------------------|--|------------------------|
| | PND 16–17 rats | <p><u>¹H spectroscopy in cortex and injured hippocampus –</u></p> <ul style="list-style-type: none"> increased L.ac/Cr (4 hrs), decreased NAA/Cr at 24 hrs and 7days; | [92] |
| | PND 16–17 rats | <p><u>¹³C-Glucose metabolism</u></p> <ul style="list-style-type: none"> 24 hr after TBI, mitochondrial metabolism was comparable to shams | [97] |
| | PND 21–22 rats | <ul style="list-style-type: none"> Decreased neuronal metabolism and/or glutaminase – decreased label in Glutamate 6 hr post TBI, delayed mitochondrial metabolism via PDH and PC with later increase labeling in ipsilateral and contralateral hemispheres | [97] [68] |
| | PND 17 rats | <ul style="list-style-type: none"> Glutamate transfer from Neurons → Astrocytes is delayed and later increased in the both sides of injured brain compared to sham Glutamine transfer from Astrocytes → Glutamatergic neurons is altered in both hemispheres | [68] |
| | PND 17 rats | <ul style="list-style-type: none"> Proteomics analyses – 2 weeks post TBI decreased expression of mitochondrial proteins – voltage-dependent anion channel 1 and 2; pyruvate dehydrogenase subunits E1alpha and beta | [151] |
| | PND 35 rats | <ul style="list-style-type: none"> Pyruvate dehydrogenase activity and mitochondrial respiratory control ratio were decreased at 4 hr post TBI Lipid metabolism – increased oxidation of cardiolipin promoting apoptosis | [152] [153] |
| | PND 21 mice | <ul style="list-style-type: none"> Increased MCT2 expression in cerebral vasculature at 24hrs after TBI Decreased ATP, Total Creatine and Creatine at 24 hr after TBI Glutathione Peroxidase did not change at 24 hr after TBI | [154] [93] [155] |

Table 3

Effects of alternative substrates and metabolic modifiers in brain injury models

| Substrates | Experimental paradigm | Alterations | Refs. |
|--|--|---|---------------------------------|
| Ketones | TBI – adult rats | 3hr continuous infusion of BHB alleviated decrease in ATP | [101] |
| Ketogenic diet | TBI - PND 35 rat | <ul style="list-style-type: none"> Improved ATP, creatine, phosphocreatine, total creatine; Improved behavioral outcome (beam walking; Morris water maze performance) Decreased contusion volume | [93] [160] [100] |
| | Carnitine and acetyl-L-carnitine | <ul style="list-style-type: none"> Carnitine treatment <u>during</u> HI decreased injury volume and number of dead cells; post treatment had no effect HI led to abnormal ratio of acyl-CoA:CoA; pretreatment with carnitine prevented changes in acyl-CoA:CoA, prevented increases in glutamate, glycine, superoxide, prevented loss of cardiolipin Treatment with acetyl-L-carnitine after TBI decreased lesion size and improved beam walking performance and novel object recognition tests ¹³C-acetyl-L-carnitine was metabolized primarily in GABAergic neurons and astrocytes in immature brain | [156] [157] [99] [102] |
| Creatine | HI in PND 10 mice | <ul style="list-style-type: none"> Supplementing diet at weaning with 1% or 3% creatine monohydrate decreased infarct size, improved locomotor and exploratory behavior and spatial memory | [98] |
| Branched chain amino acids (BCAA) | Fluid percussion trauma adult mice | <ul style="list-style-type: none"> TBI reduced BCAA content in brain, decreased synaptic efficiency (EPSP) and impaired cognition; treatment with branched chain amino acids (BCAA) normalized synaptic efficiency and improved cognition | [104] |
| Triheptanoin/trioctanoin | Epilepsy adult mice | <ul style="list-style-type: none"> Triheptanoin partially restored TCA cycle metabolites Triheptanoin increased anaplerotic metabolites | [103] [105] |
| | N-3 fatty acid enriched triglyceride emulsions | <ul style="list-style-type: none"> N-3 fatty acid enriched triglyceride emulsions administered 0–2 hr after HI decreased lesion size Tri-DHA (docosahexaenoic acid) was protective; tri-EPA (eicosapentaenoic acid) was not effective | [158] |
| XJB-5-131 (electron scavenger targeted to neuronal mitochondria) | TBI – PND 17 rats | <ul style="list-style-type: none"> Prevented cardiolipin oxidation and caspase activation; Improved mitochondrial function, decreased neuronal cell death, behavioral deficits and cortical lesion volume | [161] |